Solutions

• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • ScFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing
  • CAR Cell In Vitro Assay
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trial
  • One-Stop Canine CAR-T Therapy Development
  • One-Stop mRNA CAR-T Therapy Development
  • TRAC-CAR-T Cell Development
  • Modular CAR-T Cell Generation
  • One-Stop Silence™ CAR-T Cell Development
  • Vaccine Boosting CAR-T Cell Therapy
  • STAb-T Cell Therapy Development
  • CAR-T Therapy Development in the Non-Cancer Field
  • Anti-HIV CAR Cell Therapy Development
  • T Cell Activity Modulator Discovery
  • T Cell Programming
  • Virus Specific T Cell (VST) Development
  • Antibody-Coupled T Cell Receptor (ACTR) Development
  • Organoid-induced hPSC-original T Cell Differentiation
  • γδ T Cell Engineering
  • CAR-T CDMO
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Clinical Application
  • TCR Analysis
  • TCR Tetramerization Construction
  • ScFv-TCR T Cell Therapy Development
  • AbTCR Development
  • Bispecific TCR Development
  • CER Development
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-Stop CAR-NKT Therapy Development
  • One-Stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-Stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering
  • NK Cell Expansion
• One-Stop CAR-B Therapy Development
• One-Stop CAR-Monocyte Therapy Development
• One-Stop Cytokine Release Syndrome (CRS) Management
• TCR-Like Antibody Development
  • MHC/Peptide Complex Production
  • TCR-Like Antibody Discovery
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction & Evaluation
• In Vivo Cell Engineering Development
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• One-Stop Allogeneic Cell Therapy Development
  • Allogeneic CAR-T Therapy Development
  • Allogeneic TCR-T Therapy Development
  • Allogeneic CAR-NK Therapy Development
  • Allogeneic CAR/TCR Cell Design & Engineering
  • Other Allogeneic Cell Therapy Development
• TCR/CAR/Antigen-Engineered Tregs Development
  • CAR-Treg Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
  • Dendritic Cell Vaccine Development
• Immune Genotyping
  • HLA Typing
  • KIR Typing
  • HLA Testing
  • Dog DLA Genotyping
  • Guinea Pig GPLA Genotyping
  • Mouse H2 Genotyping
  • Rabbit RLA Genotyping
  • Rat RT1 Genotyping
  • Rhesus Macaque MHC Genotyping
• Other Services
  • Tumor-infiltrating Lymphocyte-based Antibody Discovery

CellRapeutics™ Proliferation Test Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Our CAR-T cell proliferation service provides a comprehensive solution for evaluating CAR-T cell proliferation accurately and efficiently. Our commitment to scientific excellence and client satisfaction ensures that your research projects receive the support they need to succeed.

Our Services

CAR-T cell proliferation is a key factor in cancer treatment. At Creative Biolabs, our team of scientists has extensive experience in cell biology and immunology research and is able to provide customers with comprehensive and reliable proliferation assay services to support their CAR-T research projects. We provide a wide range of cell proliferation assays including MTT, MTS, CCK-8, carboxyfluorescein succinimidyl ester (CFSE), [3H] thymidine incorporation, and other proliferation assay techniques to evaluate CAR-T cell proliferation. Each assay has specific advantages and we can tailor our assays to meet specific research. Additionally, we also offer cytokine concentration assay service to measure the level of cytokines in the cell culture supernatant, which can be used as an indicator of cell activation and proliferation.

Table 1. CAR-T cell proliferation assays.

Our Advantages

• Multiple assays available: We provide various cell proliferation assays to meet the specific needs of each research project.
• Fast turnaround time: Our experts have extensive experience to ensure that you can get your results on time.
• Accurate data interpretation and reliable results: Our team of scientists is available to provide customers with expert advice, detailed support, and reliable results on their research projects.

If you are interested in our cell proliferation assay services, please get in touch with us for more details and learn how we support your research project. Our experts are always available to provide support, assist with your projects, and ensure your success.

Support Data

Here are some representative data for CAR-T cell proliferation assays you can refer to:

Case 1: Analysis of CAR-T cell proliferation by CCK8.

Fig.1 EGFRvIII-CAR-T cell proliferation.¹

Case 2: Analysis of CAR-T cell proliferation by CFSE.

Fig.2 CD19-CAR-T cell proliferation after stimulation with IL-2 or CD19-AVs.²

Case 3: Analysis of CAR-T cell proliferation by [3H] thymidine incorporation.

Fig.3 The proliferative capacity of HER2 CAR and IL-13Rα2 CAR T cells.³

Case 4: Analysis of CAR-T cell proliferation by trypan blue staining.

Fig.4 CAR T cells proliferation over time after co-culture with different target cells.⁴

References

1. Ma, Yuan, et al. "EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma." International Journal of Medical Sciences 17.10 (2020): 1406.
2. Ukrainskaya, Valeria, et al. "Antigen‐Specific Stimulation and Expansion of CAR‐T Cells Using Membrane Vesicles as Target Cell Surrogates." Small 17.45 (2021): 2102643.
3. Hegde, Meenakshi, et al. "Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma." Molecular Therapy 21.11 (2013): 2087-2101.
4. Yazdanifar, Mahboubeh, et al. "Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma." Cells 8.9 (2019): 1070.